Objective:To study the bioinformatics-driven expression and prognostic significance of TENM1 in breast cancer (BRCA) and its effect on the proliferation and migration of MDA-MB-231 cells. Methods: TENM1 expression profiles of breast cancer tissue samples from the TCGA database were download for differential expression analysis. Survival analysis, univariate and multivariate Cox regression analysis were performed, and a Nomogram prediction model was established to validate the independent prognostic value of TENM1. Gene set enrichment analysis was used to evaluate dysregulated signaling pathways associated with TENM1 expression. After interfering and overexpressing TENM1 in MAD-MB-231 cells, proliferative capacity of cells was detected using CCK8 and clonogenic assays, and migratory capacity was detected using the Transwell migration assay. Results: TENM1 expression was decreased in breast cancer tissues comparing to normal samples. Results of survival analysis, univariate and multivariate Cox regression analysis and Nomogram prediction modeling indicated that TENM1 might be an independent prognostic factor for BRCA. GSEA analysis results showed that TENM1-related signaling pathways were selectively enriched at cell division and cell cycle. Suppression of TENM1 increased the proliferation and migration of MDA-MB-231 cells, as shown by CCK8, clonogenic assay and Transwell migration assay. Conversely, overexpression of TENM1 inhibited proliferation and migration. Conclusion: Down-regulated TENM1 expression is in breast cancer tissues could inhibit the proliferation and migration of MDA-MB-231 cells. TENM1 might be a valuable prognostic molecular marker for BRCA and a promising target for future treatment of BRCA .
LI Yating
,
FANG Lin
. Bioinformatics analysis of TENM1 and its effect on the proliferation and migration of MDA-MB-231 breast cancer cells[J]. Journal of Baotou Medical College, 2024
, 40(7)
: 9
-14
.
DOI: 10.16833/j.cnki.jbmc.2024.07.002
[1] Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2021, 71(3): 209-249.
[2] Siegel RL, Miller KD, Fuchs HE, et al. Cancer statistics, 2022[J]. CA Cancer J Clin, 2022, 72(1): 7-33.
[3] Yin J, Gu TZ, Chaudhry N, et al. Epigenetic modulation of antitumor immunity and immunotherapy response in breast cancer: biological mechanisms and clinical implications[J]. Front Immunol, 2024, 14: 1325615.
[4] Ndlovu H, Lawal IO, Mokoala KMG, et al. Imaging molecular targets and metabolic pathways in breast cancer for improved clinical management: current practice and future perspectives[J]. Int J Mol Sci, 2024, 25(3): 1575.
[5] Ou Y, Wang MC, Xu Q, et al. Small molecule agents for triple negative breast cancer: current status and future prospects[J]. Transl Oncol, 2024, 41: 101893.
[6] Zhou XH, Brandau O, Feng K, et al. The murine Ten-m/Odz genes show distinct but overlapping expression patterns during development and in adult brain[J]. Gene Expr Patterns, 2003, 3(4): 397-405.
[7] Cheng SP, Chen MJ, Chien MN, et al. Overexpression of teneurin transmembrane protein 1 is a potential marker of disease progression in papillary thyroid carcinoma[J]. Clin Exp Med, 2017, 17(4): 555-564.
[8] Sun YH, Liu ZF, Yang BB, et al. MicroRNA-486 inhibits cell proliferation, invasion and migration via down-regulating the TENM1 expressions and affecting ERK and Akt signaling pathways and epithelial-to-mesenchymal transition in papillary thyroid carcinoma[J]. Eur Rev Med Pharmacol Sci, 2019, 23(19): 8429-8439.
[9] Pan RC, Tang HP, Wang X. A five-gene prognostic nomogram predicting disease-free survival of differentiated thyroid cancer[J]. Dis Markers, 2021, 2021: 5510780.
[10] Bindea G, Mlecnik B, Tosolini M, et al. Spatiotemporal dynamics of intratumoral immune cells reveal the immune landscape in human cancer[J]. Immunity, 2013, 39(4): 782-795.
[11] Li MD, Wang HY, Qu N, et al. Breast cancer screening and early diagnosis in China: a systematic review and meta-analysis on 10.72 million women[J]. BMC Womens Health, 2024, 24(1): 97.
[12] Siegel RL, Giaquinto AN, Jemal A. Cancer statistics, 2024[J]. CA Cancer J Clin, 2024, 74(1): 12-49.
[13] Swarbrick A, Fernandez-Martinez A, Perou CM. Gene-expression profiling to decipher breast cancer inter- and intratumor heterogeneity[J]. Cold Spring Harb Perspect Med, 2024, 14(1): a041320.
[14] Pankotai-Bodó G, Oláh-Németh O, Sükösd F, et al. Routine molecular applications and recent advances in breast cancer diagnostics[J]. J Biotechnol, 2024, 380: 20-28.
[15] Singh A, Mishra R, Mazumder A. Breast cancer and its therapeutic targets: a comprehensive review[J]. Chem Biol Drug Des, 2024, 103(1): e14384.
[16] Criscitiello C, Esposito A, Trapani D, et al. Prognostic and predictive value of tumor infiltrating lymphocytes in early breast cancer[J]. Cancer Treat Rev, 2016, 50: 205-207.
[17] Yamaguchi K, Mishima K, Ohmura H, et al. Activation of central/effector memory T cells and T-helper 1 polarization in malignant melanoma patients treated with anti-programmed death-1 antibody[J]. Cancer Sci, 2018, 109(10): 3032-3042.
